US/UK/Canada

Share

Contacts

  • Dag Bergheim Pettersen

    CEO


    Hulda Mellgrens gata 5 421 32 Västra Frölunda Sweden
    +46 (0) 31 771 71 50
    http://www.zinzino.com
    • Pick a time period -
    Tags ( Active)

    ZINZINO AB (PUBL.): INTERIM REPORT THIRD QUARTER 2024

    CONTINUED STRONG GROWTH IN THE THIRD QUARTER Revenues in the third quarter of 2024 amounted to SEK 532.8 (436.9) million, corresponding to 22% (25%) growth compared to the corresponding period last year. In local currencies, revenues increased by 24% compared to the third quarter of the previous year. EBITDA profit amounted to SEK 63.0 (71.2) million and the EBITDA margin was 11.8% (16.3%). The EBITDA margin was compared to a very strong third quarter last year and the change was mainly due to the marginally weaker gross profit for the quarter because of increased raw material prices and

    ZINZINO AB (PUBL): Zinzino announces Canary Islands as next step in its global expansion

    Zinzino is pleased to announce that it will launch its operations in the Canary Islands on November 13, 2024. A comprehensive business ecosystem, an attractive tax system and a favorable climate for an active lifestyle have all made the islands a natural backdrop for many national and international entrepreneurs within the health and wellness industry. This archipelagic Spanish region represents a strategic next step in Zinzino’s plan to expand its customer base on an international scale. The launch will enable the company’s Independent Partners to continue building locally and growing

    ZINZINO AB (PUBL): PRELIMINARY SALES REPORT OCTOBER 2024

    Zinzino group revenue increased with a total of 20 %, compared with the previous year. The revenue in October for Zinzino's sales markets increased by 20 % and amounted to SEK 190.0 (157.7) million. Faun Pharma's external sales increased by 19 % and amounted to SEK 7.4 (6.2) million. Overall, the Group increased revenues by 20 % to SEK 197.4 (163.9) million compared with the previous year. Accumulated revenue for January – October 2024 increased by 21 % to SEK 1691.7 (1402.4) million. Revenues were distributed as follows: Regions,MSEK 24 23 Change YTD 2024 YTD

    ZINZINO AB (PUBL): PRELIMINARY SALES REPORT Q3 2024

    Zinzino group revenue increased 22% in Q3, compared with the previous year. The revenue in September for Zinzino's sales markets increased by 20 % and amounted to SEK 177.8 (148.3) million. Faun Pharma's external sales decreased and amounted to SEK 5.8 (9.9) million. Overall, the Group increased revenues by 16% to SEK 183.6 (158.2) million compared with the previous year. Sales in Zinzino's sales markets increased by 22% in the third quarter of 2024 compared with the same period last year and amounted to SEK 503.9 (413.8) million. Total revenues in the Group increased by 22 % in the

    ZINZINO AB (PUBL): Share subscription due to directed set-off issues

    The company's Board of Directors has, based on the registered issue authorization from the Annual General Meeting on May 31, 2023, during the Board meeting on May 12, 2024, decided on a new issue with payment by set-off. According to the decision, a total of 147,000 new Zinzino B shares have been issued with payment by way of set-off of the claim to Xelliss Luxembourg SA, Xelliss North America and Prolex Technologies SA. The transaction is linked to the acquisition of the assets of the Xelliss group on 2024-05-12. In accordance with the resolution of the Annual General Meeting on May 27,

    ZINZINO AB (PUBL): PRELIMINARY SALES REPORT AUGUST 2024

    Zinzino group revenue increased with a total of 39 %, compared with the previous year. The revenue in August for Zinzino's sales markets increased by 38 % and amounted to SEK 166.4 (120.6) million. Faun Pharma's external sales increased by 58 % and amounted to SEK 12.3 (7.8) million. Overall, the Group increased revenues by 39 % to SEK 178.7 (128.4) million compared with the previous year. Accumulated revenue for January – August 2024 increased by 21 % to SEK 1309.4 (1080.3) million. Revenues were distributed as follows: Regions,MSEK 24 23 Change YTD YTD

    ZINZINO AB (PUBL): INTERIM REPORT SECOND QUARTER 2024

    STRONG GROWTH AND PROFITABILITY DURING AN EVENTFUL QUARTER Revenues in the second quarter of 2024 amounted to SEK 507.0 (407.9) million, corresponding to 24% (24%) growth compared to the corresponding period last year. EBITDA increased to SEK 63.0 (53.7) million, and the EBITDA margin amounted to 12.4% (13.2%). During the quarter, Zinzino acquired the rights to Luxembourg-based Xelliss SA distributor database, inventory and IP assets, acquired 49% of the shares in the Cypriot olive oil producer Cleanthi Alpha-Olenic LTD and signed a letter of intent to acquire the US direct sales company

    ZINZINO AB (PUBL): PRELIMINARY SALES REPORT JULY 2024

    Zinzino group revenue increased with a total of 13 %, compared with the previous year. The revenue in July for Zinzino's sales markets increased by 10 % and amounted to SEK 159.3 (145.0) million. Faun Pharma's external sales increased by 91 % and amounted to SEK 10.3 (5.4) million. Overall, the Group increased revenues by 13 % to SEK 169.9 (150.4) million compared with the previous year. Accumulated revenue for January – July 2024 increased by 19 % to SEK 1131.2 (952.0) million. Revenues were distributed as follows: Regions,MSEK 24 23 Change YTD YTD 2023

    ZINZINO AB (PUBL): PRELIMINARY SALES REPORT Q2 2024

    Zinzino group revenue increased 24% in Q2, compared with the previous year. The revenue in June for Zinzino's sales markets increased by 13% and amounted to SEK 148.5 (131.4) million. Faun Pharma's external sales decreased and amounted to SEK 5.8 (8.5) million. Overall, the Group increased revenues by 10% to SEK 154.3 (139.9) million compared with the previous year. Revenue in Zinzino's sales markets increased by 24% in the second quarter of 2024 compared with the same period last year and amounted to SEK 481.9 (387.3) million. Total revenues in the Group increased by 24% in the

    ZINZINO AB (PUBL.): ZINZINO ACQUIRES 49% OF CYPRIOT OLIVE OIL PRODUCER CLEANTHI ALPHA-OLENIC LTD

    Zinzino has today acquired 49% of the shares and votes in the Cypriot olive oil producer Cleanthi Alpha-Olenic LTD ("Cleanthi or the Company"). The acquisition is another strategically important step in Zinzino's growth plans focused on improving personal health and well-being on a global scale with innovative biotechnology and a pioneering product portfolio marketed through direct sales. Cleanthi is an olive oil producer with a unique and patented process of pressing olive oil originating from certified Koreneiki olives from orchards owned by farmers for several generations without the

    ZINZINO AB (PUBL): LETTER OF INTENT TO ACQUIRE ZURVITA INCREASES DISTRIBUTION POWER IN NORTH AMERICA

    Zinzino, has today signed a letter of intent with the shareholders of the North American direct selling company Zurvita Inc. "Zurvita or the Company" to acquire 100% of the shares in the Company. This is another strategically important step in Zinzino's growth plans focused on improving personal health and wellness on a global scale with innovative biotechnology and a groundbreaking product portfolio marketed through direct sales. Zurvita is a direct selling health company with operations in the United States, Canada and Mexico. The brand portfolio offers a range of innovative health and

    ZINZINO AB (PUBL): Zinzino announces Serbia as next step in its global expansion

    Zinzino is pleased to announce that it will launch its operations in Serbia on June 11, 2024. The Balkan region and Southeastern Europe represent a strategic next step in the company's plan to expand its customer base in the international market. The launch will enable Zinzino's Independent Partners to continue building locally and growing globally. Serbia's strategic location in Southeastern Europe makes it an important hub for banking, trade, and transportation in the region. The launch is expected to stimulate sales growth in Serbia as well as in the surrounding countries in the

    ZINZINO AB (PUBL): ANNUAL REPORT ENGLISH 2023

    Zinzino AB (publ.) announces that the Annual Report for 2023 is now available for download in English at the company’s website, www.zinzino.com. Link to the report:https://www.zinzino.com/site/GB/en-GB/about/investor-relations/ For more information:Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com Pictures for publication free of charge:marketing@zinzino.com Certified Adviser: Carnegie Investment Bank AB (publ)

    ZINZINO AB (PUBL): Zinzino now seeks acquisitions in the US and Asia to increase distribution power

    Zinzino, a global direct sales company from Scandinavia pioneering personalized nutrition and preventative health, is actively pursuing acquisitions across the US and Asia to enhance their business strategy for sustainable, profitable growth. CEO Dag Bergheim Pettersen reveals that their primary targets of interest are focused on increased distribution power, with product portfolios within dietary supplements being an added bonus. · We are mainly looking to maintain sustainable, profitable growth by accessing new markets to leverage our product portfolio within new consumer areas,

    ZINZINO AB (PUBL): PRELIMINARY SALES REPORT MAY 2024

    Zinzino group revenue increased with a total of 24 %, compared with the previous year. The revenue in May for Zinzino's sales markets increased by 23 % and amounted to SEK 172.3 (139.9) million. Faun Pharma's external sales increased by 31 % and amounted to SEK 9.2 (7.0) million. Overall, the Group increased revenues by 24 % to SEK 181.5 (146.9) million compared with the previous year. Accumulated revenue for January – May 2024 increased by 21 % to SEK 802.2 (661.8) million. Revenues were distributed as follows: Regions,MSEK 24 23 Change YTD YTD 2023

    ZINZINO AB (PUBL): Announcement from the annual general meeting

    Zinzino AB (publ.) held an annual general meeting today, May 27, 2024, where it was mainly decided: · to determine profit and loss accounts and balance sheets for the parent company and the group, · to distribute SEK 3.00 per share for the financial year 2023 and transfer the remaining part of the balanced profit in a new account, · to grant the board and CEO discharge from liability, · to elect Hans Jacobsson as chairman of the board and Staffan Hillberg, Pierre Mårtensson, Ingela Nordenhav and Anna Frick as other board members, · that a total of SEK 1,180,000 in board

    ZINZINO AB (PUBL): INTERIM REPORT FIRST QUARTER 2024

    TOWARDS NEW HEIGHTS AFTER A PROFITABLE AND INTENSE QUARTER Revenues in the first quarter of 2024 amounted to SEK 454.5 (393.7) million, corresponding to 15% (18%) growth compared to the corresponding period last year. EBITDA increased to SEK 51.7 (40.8) million and the EBITDA margin to 11.4% (11.3%). During the quarter, a strategic partnership in Europe was entered into with the North American direct sales company ACN, which also invested in 149,468 Zinzino B shares via a directed share issue of SEK 10.4 million. After the end of the period, Zinzino acquired the rights to the Luxembourg-

    ZINZINO AB (PUBL): Zinzino acquires assets in Xelliss – strategic reinforcement in southern Europe and in the microalgae spirulina

    Zinzino, the global health and wellness brand from Scandinavia, has acquired, through a business asset acquisition, the rights to the distributor database and associated customer register, inventory, and intellectual property of the Luxembourg-based direct sales company Xelliss. This is a further strategically important step in Zinzino's growth plans, focusing on improving personal health and well-being on a global level with innovative biotechnology and a groundbreaking product portfolio marketed through direct sales. Xelliss is a global direct sales company based in Luxembourg. Its

    ZINZINO AB (PUBL): PRELIMINARY SALES REPORT APRIL 2024

    Zinzino group revenue increased with a total of 35 %, compared with the previous year. The revenue in April for Zinzino's sales markets increased by 34 % and amounted to SEK 155.7 (116.0) million. Faun Pharma's external sales increased by 54 % and amounted to SEK 8.0 (5.2) million. Overall, the Group increased revenues by 35 % to SEK 163.7 (121.2) million compared with the previous year. Accumulated revenue for January – April 2024 increased by 20 % to SEK 618.2 (514.9) million. Revenues were distributed as follows: Regions,MSEK 24 23 Change YTD YTD 2023

    ANNUAL REPORT 2023 ZINZINO AB (PUBL)

    Zinzino (publ) announces that the company's annual report for 2023 in Swedish is now published on the company's website, zinzino.com.  The English version will be published within approximately 45 days. The 2024 Annual General Meeting will be held at the company's premises at Hulda Mellgrens gata 5 in Västra Frölunda on May 27 at 1:30 p.m. The nomination committee's proposals for board members, the board's remuneration and auditors are presented in the notice to the annual general meeting. For further information about the annual general meeting, refer to the company's website www.

    ZINZINO AB (PUBL): NOTICE OF ANNUAL GENERAL MEETING IN ZINZINO AB ON MAY 27, 2024

    Shareholders of Zinzino AB (publ) are hereby invited to the annual general meeting on Monday, May 27, 2024, at 1:30 PM at the company's premises at Hulda Mellgrens gata 5 in Gothenburg. Registration begins at 1:15 PM. The company aims to webcast the meeting to enable remote participation. RIGHT TO PARTICIPATE IN THE COMPANY MEETING Shareholders wishing to attend the annual general meeting must: i. be entered in the shareholder register maintained by Euroclear Sweden AB by Friday, May 17, 2024, and ii. have notified their intention to attend the meeting by Friday, May 24,

    ZINZINO AB (PUBL): PRELIMINARY SALES REPORT Q1 2024

    Zinzino group revenue increased with a total of 14 % in Q1 compared with the previous year. The revenue in March for Zinzino's sales markets increased by 9% and amounted to SEK 148.9 (136.2) million. Faun Pharma's external sales decreased with 1 % and amounted to SEK 9.7 (9.8) million. Overall, the Group increased revenues by 9% to SEK 158.6 (146.0) million compared with the previous year. The group revenue increased with 14 % for Q1 2024 compared with the first quarter last year and amounted to SEK 450.4 (393.7) million. Revenues were distributed as follows: Regions, 24-mar

    ZINZINO AB (PUBL): PRELIMINARY SALES REPORT FEBRUARY 2024

    Zinzino group revenue increased with a total of 25 %, compared with the previous year. The revenue in February for Zinzino's sales markets increased by 27 % and amounted to SEK 138.7 (109.6) million. Faun Pharma's external sales increased by 11 % and amounted to SEK 9.7 (8.7) million. Overall, the Group increased revenues by 25 % to SEK 148.4 (118.3) million compared with the previous year. Accumulated revenue for January – February 2024 increased by 20 % to SEK 297.4 (247.8) million. Revenues were distributed as follows: Regions,MSEK 24 23 Change YTD 2024 YTD 2023

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media